Uscom Limited designs, develops, manufactures, and markets non-invasive cardiovascular and pulmonary medical devices worldwide.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.14|
|52 Week High||AU$0.12|
|52 Week Low||AU$0.19|
|1 Month Change||0%|
|3 Month Change||-10.00%|
|1 Year Change||-25.00%|
|3 Year Change||-3.57%|
|5 Year Change||-46.00%|
|Change since IPO||-94.38%|
Recent News & Updates
|UCM||AU Medical Equipment||AU Market|
Return vs Industry: UCM underperformed the Australian Medical Equipment industry which returned -7.4% over the past year.
Return vs Market: UCM underperformed the Australian Market which returned 24.4% over the past year.
Stable Share Price: UCM is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: UCM's weekly volatility (8%) has been stable over the past year.
About the Company
Uscom Limited designs, develops, manufactures, and markets non-invasive cardiovascular and pulmonary medical devices worldwide. It offers USCOM 1A, a non-invasive hemodynamic monitor that measures cardiovascular function using Doppler ultrasound; BP+, a supra-systolic oscillometric central blood pressure monitor that measures blood pressure and blood pressure waveforms at the heart, as well as in the arm; and SpiroSonic, a pulmonary function testing device based on multi-path ultrasound technology. The company provides the SpiroSonic AIR, a digital home care spirometer which feeds digital lung function signals through a phone app; and Ventitest, a digital ultrasonic ventilator testing solution for testing ventilators.
Uscom Fundamentals Summary
|UCM fundamental statistics|
Is UCM overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|UCM income statement (TTM)|
|Cost of Revenue||AU$485.07k|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.0059|
|Net Profit Margin||-20.29%|
How did UCM perform over the long term?See historical performance and comparison
Is Uscom undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate UCM's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate UCM's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: UCM is unprofitable, so we can't compare its PE Ratio to the Australian Medical Equipment industry average.
PE vs Market: UCM is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate UCM's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: UCM is overvalued based on its PB Ratio (6.9x) compared to the AU Medical Equipment industry average (4.5x).
How is Uscom forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Uscom has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Uscom performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: UCM is currently unprofitable.
Growing Profit Margin: UCM is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: UCM is unprofitable, but has reduced losses over the past 5 years at a rate of 16.8% per year.
Accelerating Growth: Unable to compare UCM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: UCM is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (74.9%).
Return on Equity
High ROE: UCM has a negative Return on Equity (-30.03%), as it is currently unprofitable.
How is Uscom's financial position?
Financial Position Analysis
Short Term Liabilities: UCM's short term assets (A$3.5M) exceed its short term liabilities (A$948.8K).
Long Term Liabilities: UCM's short term assets (A$3.5M) exceed its long term liabilities (A$1.3M).
Debt to Equity History and Analysis
Debt Level: UCM is debt free.
Reducing Debt: UCM has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable UCM has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: UCM is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 21% per year.
What is Uscom current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate UCM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate UCM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if UCM's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if UCM's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of UCM's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Rob Phillips (68 yo)
Dr. Robert Allan Phillips, also known as Rob, Ph D.(Med), MPhil (Med), FASE, DMU, AMS, FIR, is the Founder of Uscom Limited and serves as its Chief Scientist. Dr. Phillips has been the Chief Executive Offi...
CEO Compensation Analysis
Compensation vs Market: Rob's total compensation ($USD514.15K) is above average for companies of similar size in the Australian market ($USD301.38K).
Compensation vs Earnings: Rob's compensation has increased whilst the company is unprofitable.
Experienced Board: UCM's board of directors are considered experienced (3.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4%.
Uscom Limited's employee growth, exchange listings and data sources
- Name: Uscom Limited
- Ticker: UCM
- Exchange: ASX
- Founded: 1999
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: AU$20.357m
- Shares outstanding: 156.59m
- Website: https://www.uscom.com.au
Number of Employees
- Uscom Limited
- 66 Clarence Street
- Suite 2
- New South Wales
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/26 07:02|
|End of Day Share Price||2021/10/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.